Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus

Journal of Viral Hepatitis

Volumn 23, Issue 8, 2016, Pages 623-630

  Younossi, Z M ^a,b   Stepanova, M ^c   Henry, L ^c   Younossi, I ^c   Weinstein, A ^c   Nader, F ^a   Hunt, S ^c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

Author keywords

hepatitis C; quality of life; work productivity

Indexed keywords

ABSENTEEISM; ADULT; ANXIETY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; EMPLOYMENT; ENERGY; FATIGUE; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PREDICTION; PRESENTEEISM; PRIORITY JOURNAL; PRODUCTIVITY; QUESTIONNAIRE; RATING SCALE; SELF REPORT; SHORT FORM 36; WELLBEING; WORK;

EID: 84978709118     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12528     Document Type: Article

References (33)

1. Anonymous. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection. Geneva: World Health Organization, 2014.
2. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61(1 Suppl): S58–S68.
3. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36(6): 1439–1445.
4. Louie KS, St Laurent S, Forssen UM. et al. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis 2012; 12: 86.
5. Younossi ZM, Kanwal F, Saab S et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014; 39(5): 518–531.
6. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10(9): 553–562.
7. Leone N, Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 2005; 51(1): 31–46.
8. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014; 46(Suppl 5): S186–S196.
9. Escorpizo R. Understanding work productivity and its application to work-related musculoskeletal disorders. Int J Ind Ergon 2008; 38(3–4): 291–297.
10. Mchutchison JG, Ware JE, Bayliss MS et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34(1): 140–147.
11. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C–the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015; 41(6): 497–520.
12. DiBonaventura M, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray KW. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 2011; 14: 253–261.
13. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 2010; 52(2): 436–442.
14. Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care 2011; 17(10): 657–664.
15. Baran RW, Samp JC, Walker DR et al. Costs and absence of HCV-infected employees by disease stage. J Med Econ 2015; 18(9): 691–703.
16. John-Baptiste AA, Tomlinson G, Hsu PC et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009; 104(10): 2439–2448.
17. Younossi ZM, Stepanova M, Henry L et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014; 60(4): 741–747.
18. Younossi ZM, Stepanova M, Zeuzem S et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 2014; 61(2): 228–234.
19. Younossi ZM, Stepanova M, Afdhal N et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015; 63(2): 337–345.
20. Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: insights from a work productivity economic model from the United States. Hepatology 2015; 61(5): 1471–1478.
21. Younossi Z, Brown A, Buti M et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat 2016; 23(3): 217–226.
22. Younossi ZM, Stepanova M, Pol S, Bronowicki JP, Carrieri MP, Bourlière M. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int 2016; 36(1): 42–48.
23. Younossi ZM, Stepanova M, Sulkowski M et al. sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis 2015; 212(3): 367–377.
24. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368(20): 1878–1887.
25. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368(20): 1867–1877.
26. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370(20): 1889–1898.
27. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370(16): 1483–1493.
28. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370(21): 1993–2001.
29. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370(20): 1879–1888.
30. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45: 295–300.
31. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med 2001; 33(5): 350–357.
32. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 1993; 11(3): 570–579.
33. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353–365.